(AMGN - Get Report)
: ABX-EGF, third-line colon cancer study, second half 2005;
: Milnacipran, fibromyalgia phase III, third quarter 2005;
: Lucentis, age-related macular degeneration phase IIII, third quarter 2005. Avastin, front-line lung cancer phase III, second half 2005;
: Efaproxyn, brain metastases from lung cancer phase III, fourth quarter 2005;
: Telcyta, ovarian non-small-cell lung cancer phase III, fourth quarter 2005;
: Provenge, prostate cancer phase III, second half/fourth quarter 2005;
: Xcytrin, brain metastases from lung cancer phase III, second half 2005.
: Polyheme, blood substitute trauma phase III, year-end 2005;
: Canvaxin, melanoma phase III, end of 2005.
Turning the Page
On a calendar note of a personal sort, today marks my last day at
After four wonderful years here and 15 years as a business journalist, it's time for a new challenge. Next week, I'll be joining a New York-based investment firm as a biotech analyst (I'll remain on the West Coast.) I've been writing about biotech investing for a long time, so now's my chance to see if I can actually invest in biotech -- and make money doing it.
I'm excited to start the new gig, but I leave
with some reluctance, because this has been (and continues to be) a great place to work and learn. I look back over the past four years and I marvel at how much I've learned about the way Wall Street really works. My investment education only accelerated when I was fortunate to join the staff of
two years ago.
Thanks to Jim Cramer, Dave Morrow, the entire cast of
contributors and all the writers and editors at
. It's been a great ride.
Finally, thanks to all my readers! Your constant feedback -- both naughty and nice -- kept me constantly energized and on my toes. I met some amazingly smart and friendly people through this Web site, readers who became trusted sources and helped me appear smarter than I am. I'm thankful and better for it, and will miss that part of the job more than anything.
Next week, I stop watching and start doing. I can't wait to get started. Thanks again, and continued success to all.